57 results about "Kidney transplant" patented technology

The invention relates to highly concentrated DHA and EPA formulations in a soft gel capsule. A capsule may contain at least 80% omega-3 fatty acids, salts or derivatives thereof, where EPA and DHA are present in relative amounts of greater than or equal to 3:1 or less than or equal to 1:3, and constitute at least 75% to greater than 95% of the total fatty acids present in the capsule. Capsules of the invention may be provided in a blister package so as to provide clean and protected oils that are easy to travel with. Compliance is improved with one-pill-a-day dosing and the days of the week imprinted on the foil packing. Anitoxidant protection may be provided by rosemary and vitamin C. The invention also provides a methods of treatment, modulation or prophalaxis of coronary disease, altering serum LDL-cholesterol and / or HDL-cholesterol, lowering serum triglycerides, lowering blood pressure, pulse rate, altering the activity of the blood coagulation factor VII complex, mild hypertension, protection from cyclosporine toxicity in kidney transplant, rheumatoid arthritis, development and progression of retinopathy, hypertriglyceridemia, and neurological disorders in a subject.

The present invention relates to methods of prognosing the survival of a diseased subject, particularly a subject with chronic kidney disease (CKD), as well as selecting an end-stage renal disease subject for a kidney transplant. The methods involve detecting an elevated amount of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample from the diseased subject. A method of preventing or reducing the risk of death in a CKD subject which involves removing or inactivating MIC-1 present in the blood, plasma or serum of the subject, is also disclosed.

Methods for the treatment of acute renal failure, multi-organ failure, early dysfunction of kidney transplant, chronic renal failure, organ dysfunction, and wound healing are provided. The methods include delivering a therapeutic amount of hematopoietic stem cells, non-hematopoietic, mesenchymal stem cells, hemangioblasts, and pre-differentiated cells to a patient in need thereof.

The present invention relates to HLA-A*02-restricted cellular epitopes within the VP1 polypeptide of a human polyomavirus, BK virus, which is associated with polyomavirus-associated nephropathy in kidney transplant patients. Preferred peptides correspond to amino acids residues 107-116, 108-116 and 44-52 of BKV VP1, and are processed in vivo in natural infection with BKV. Effector T cell populations stimulated by the peptides represent functional CTLs as assessed by cytotoxicity and cytokine production, and are reactive against cells presenting both the BKV peptides above and the JC virus homolog sequences.

The invention discloses an intraoperative low temperature kidney protective bag and a using method thereof. The intraoperative low temperature kidney protective bag comprises a protective bag body, acool storage interlayer, inner layer folds, a cold storage infusion port, a kidney placing inlet and a kidney gate opening. The cool storage interlayer is arranged in the protective bag body; the inner wall of the protective bag body is provided with the inner layer folds, and the inner layer folds enclose to form an inner cavity; the inner cavity is filled with kidney protection liquid; the upperpart of the protective bag body is provided with the kidney placing inlet, a first elastic rubber ring is arranged at the kidney placing inlet, the lower part of the protective bag body is provided with the kidney gate opening, and a second elastic rubber ring is arranged at the kidney gate opening; the first elastic rubber ring and the second elastic rubber are both provided with elastic retractable ropes. The intraoperative low temperature kidney protective bag can ensure cryopreservation effect of a kidney during a kidney transplant operation process, and effectively improve preservation quality of the kidney. The intraoperative low temperature kidney protective bag is an easy-to-operate special refrigerated storage bag for transplanted kidney, and can be specially used in a kidney transplant operation.

The invention relates to a sustained release tablet dosage, in particular to a Tacrolimus sustained release tablet used for liver and kidney transplantation patients and a preparation method thereof, belonging to the field of medicine technology. The invention is characterized in that Tacrolimus and adhesive are taken and dissolved in ethanol to prepare Tacrolimus solution; sustained release materials, thinner and flow agent are taken, mixed and dispersed uniformly and then added into the Tacrolimus solution to prepare wet particles, which are dried, ground and added and mixed with lubricant; finally, the Tacrolimus sustained release tablet is prepared after tabletting and drying. The sustained release tablet has the unique advantages of: reducing administration times, improving the administration adaptability of patients; after administration, having stable blood concentration, small toxic and side effects and improving the drug effect and safety; reducing the total dosage of drugs so as to achieve the greatest curative effect by the lowest dosage; being capable of being realized on most of tablet production lines and easily accepted by manufacturing units and manufacturers due to relatively simple preparation process; and having relatively low manufacturing cost and broad clinical application prospect.

Methods and a composition for the treatment of organ dysfunction, acute renal failure, multi-organ failure, early dysfunction of kidney transplant, graft rejection, chronic renal failure, wounds, and inflammatory disorders including media conditioned by mesenchymal stem cells are provided. Methods for modulation of growth factor and cytokine expression including administering a therapeutic amount of mesenchymal stem cells, endothelial cells derived from mesenchymal stem cells, or media conditioned by mesenchymal stem cells are also provided.

The invention relates to a kit for diagnosing post-kidney transplant acute rejection reaction, which is characterized by consisting of bioproteins, enzyme-labelled antibody of the bioprotein, carbonate buffer solution with a pH value of 9.6, phosphate buffer solution with a pH value of 7.4, haemocyanin diluents, stop solution, tetramethylbenzidine substrate solution, normal human serum and positive control serum, wherein the bioproteins are 20 bioproteins including protein S100-A8, protein S100-A9, ITIH3 precursor, IGFBP2 precursor, hemopexin precursor and the like. The invention provides the use of the 20 bioproteins including complements, cell factors, fibrin, binding proteins and other various bioproteins or the use of the combination of the 20 bioproteins with other clinical indexes as the main index for diagnosing the post-kidney transplant acute rejection reaction.

The invention belongs to the field of biotechnology and discloses an antibody composition and application thereof. The anti-body composition comprises a BLC specific antibody or comprises a Fractalkine specific antibody, a Mig specific antibody and a C4d specific antibody. The antibody composition can be used for diagnosing acute rejection after kidney transplant at one time and can be used for accurately diagnosing that the acute rejection belongs to the type of cellular rejection or antibody-mediated rejection. A detection reagent prepared by using the antibody composition overcomes the defect that current acute rejection diagnosis is only limited on renal biopsy and provides a noninvasive method for clinically diagnosing acute rejection of kidney transplant and acute rejection types ofkidney transplant.

The invention relates to an early warning kit, and in particular relates to a kit for early warning transplant kidney rejection reaction and a use method of the kit. A transplant kidney rejection reaction early diagnosis system is built by monitoring and comprehensively analyzing the expression levels of 96 cell factors / chemotactic factors in 266 serums of 142 patients with acute transplant kidney rejection reaction and transplant recipients with stable transplant kidney functions and receptors of the cell factors / chemotactic factors by applying the liquid protein chip luminex detection technology and the acute rejection reaction prediction and accuracy rates of the system are 98.6% and the internal cross validation rates of the system are respectively 97.1% and 97.2%.

A tacrolimus slow-release mini-pill and a preparation method thereof are disclosed, the tacrolimus slow-release mini-pill includes a drug-containing mini-pill and a coating layer, the drug-containing mini-pill is coated with the coating layer, the drug-containing mini-pill comprises 5mg of tacrolimus, 70mg of a blank pill core, 120-220mg of a filler, 25-125mg of a lubricant and 5-50mg of a binder, the coating layer comprises 35-175mg of Eudragit NE30D and 5-52mg of talc powder, preparation steps of the preparation method are as follows: 1, preparing materials; 2, mixing; 3, preparing the binder; 4, pelleting; 5, preparing a coating agent; 6, coating; 7, filling; and 8, aluminum molding and finishing. The tacrolimus slow-release mini-pill is used for preventing of graft rejection reaction after liver or kidney transplantation and treatment of graft rejection reaction which cannot be controlled by other immunosuppressive drugs after liver or kidney transplantation, and the tacrolimus slow-release mini-pill is more secure, better in stability, and smaller in adverse reactions.

Methods of screening for expression of an RNA associated with a post-kidney transplant complication include collecting vesicles from urine, isolating vesicle-associated RNA, and analyzing expression patterns. In particular, AIF1, BTN3A3, CCL5, CD48, HAVCR1, or SLC6A6 mRNA expression patterns are analyzed.

The invention provides a kidney surgery model capable of simulating blood circulating and urine generating functions. Compared with existing kidney simulation devices which are appearance models onlyand have the problems of being simple in structure, unitary in function, low in simulation degree and unsupportive of teaching demonstration and surgery operation, the kidney surgery model can be usedfor preclinical teaching and scientific research. The model simulating human kidney organs and parts thereof is made according to a proportion of 1:1, thereby being high in simulation level, and a relation between kidney blood circulation and urine generation can be simulated through a pulse pump, a pressure control part and a valve; parts of the model are assembled and spliced, so that the modelcan be used for clinical surgical operation and teaching demonstration, medical staff can simulate related process operations of a kidney transplanting surgery, and understanding on kidney organ andsurgical success rate of the medical staff are improved.

The present invention relates to a medicine for treating chronic renal failure. The chronic renal failure is the final result of various kidney diseases, but without effective western medicine in clinic yet, and dialysis therapy and renal transplantation price are expensive and not suitable for early and middle patients. The medicine whole formula of the present invention both activates and tonifies, consideration to right and evil, nourishing and releasing integrated, leading nourishing not stagnating evil, releasing not injuring right, can not only delay chronic renal failure course, but also improve or eliminate clinical symptoms, having good curative effect, lower cost characteristic. The present invention concretely is with radix astragali, poria, hedyotis diffusa, serissa foetida, pyrola calliantha, ligusticum chuanxiong, morinda officinalis how, centella asiatica, prepared rhubarb and etc. traditional Chinese medicine to prepare into compound preparation. The present invention also relates to the medicine preparation method. As pharmacological experiment shows the present invention can obviously decrease adenine causing chronic renal failure rat and nephrectomy causing chronic renal failure rat kidney function Crea and BUN value, the present invention can also obviously increase water load rat urinary volume.

The present invention relates generally to methods of for the prevention and treatment for renal disease. In particular, the invention relates to methods of prevention and treatment of mammals, including humans, which are at risk of developing renal failure. This is generally in the field of treatment or prevention of acute renal failure by administration of the anti-apoptotic molecule survivin. The invention also includes the treatment of kidney transplants (renal allografts) to prolong survival of the graft during cold ischemia and immediately after transplantation.

The invention provides the use of a glucocorticoid having a first pass metabolism in the liver of at least 90 % as active substance, for the manufacturing of a medicament for oral or rectal administration in the treatment of glomerulonephritis by releasing the active substance in the intestine. The invention also provides a method for treatment of glomerulonephritis in a native kidney or a kidney transplant with the glucocorticoid as defined above. The invention also comprises a composition comprising the active substance and a pharmaceutically acceptable carrier, adjuvant or diluent designed for oral or rectal administration.

The invention belongs to the technical field of kidney-invigorating medicaments, and proposes a traditional Chinese medicine formula for nourishing the kidney and strengthening the essence. 54 parts, 55-65 parts of white peony root, 68-74 parts of salvia miltiorrhiza, 57-64 parts of Poria cocos, 40-55 parts of Atractylodes macrocephala, 37-43 parts of licorice, 56-65 parts of Chuan Duan, 66-74 parts of plantain seed, yam 78-83 parts, 36-44 parts of wolfberry, 37-45 parts of astragalus, 3 parts of clams, 46-53 parts of cinnamon sticks, 37-43 parts of Polygonatum odoratum, 57-64 parts of ginseng, 57-62 parts of antler, 28-28 parts of dodder 34 parts, 28-33 parts of winter melon skin, 35-44 parts of elm white skin, 38-43 parts of Akebia, 46-53 parts of red bean, 67-74 parts of barley, 57-63 parts of Panax notoginseng, 35-46 parts of hippocampus. Also proposed is a Yishen Guyuan decoction, which is composed of rice wine and Yishen Guyuan traditional Chinese medicine formula, and the weight ratio of the Yishen Guyuan Chinese medicine formula to rice wine is 500:30-36. The invention has ingenious conception and simple and convenient operation, and solves the technical problem in the prior art that Western medicine, dialysis or kidney replacement is often used, which is harmful to the human body.

The invention discloses a bed nursing and rehabilitation integrated device for a patient after the clinical kidney transplantation operation. The device is characterized in that firstly, through the cooperative action of a second electric push rod, a protective cover and an air purifier, not only can a wound be isolated from the outside to achieve the purposes of preventing infection and pressure, but also the body of the patient can be fixed to effectively prevent the condition that secondary hurt is caused when the patient turns over in the sleeping process, the healing effect of the wound is also improved, secondly, by means of the combination of a second stepping motor, a third electric push rod, a fourth electric push rod, a first connecting frame and lower limb exercise sleeves, stretching exercise of the lower limbs of the patient can be achieved, blood circulation of the legs of the patient is promoted, and complications are effectively avoided; and finally, by means of a third stepping motor, a fifth electric push rod, a sixth electric push rod, a second connecting frame, regulation and control blocks, guide sleeves and telescopic rods, the upper limbs of the patient can be exercised, besides, convenient adjustment can be achieved, and the nursing and rehabilitation requirements of the patient after the clinical kidney transplantation operation are finally met.

The invention relates to a new application of lettuce glucoside B, and particularly relates to an application of the lettuce glucoside B in preparation of medicines for prevention and treatment of kidney transplant. Experiments show that the lettuce glucoside B can be used for improving the renal function of rats subjected to kidney transplant and prolonging the survival time of the transplant kidney, the effects take on dosage dependency relationship, and the lettuce glucoside has a treatment effect on the transplant kidney.

The invention discloses an isolated kidney perfusion system, and relates to the technical field of kidney transplantation. According to the invention, a liquid conveying pipeline is used as a main body; a liquid inlet pipe, a liquid dripping bucket, a fluid speed regulation roller and an outflow assembly are sequentially arranged on the conveying pipeline in series; and through arrangement of theabove-mentioned structures, the isolated kidney perfusion system provided by the invention can make up the defect that a perfusion device used in the kidney transplantation process in the prior art isgenerally a self-made simple device and is inconvenient when a plurality of blood vessels are encountered or the blood vessels are thin. During kidney perfusion, a medicine can be injected through above-mentioned devices; a flow speed can be adjusted through a pulley; a pressure can be generated during liquid conversion and extrusion through a soft ball to facilitate perfusion; a proper siliconetube can be selected for perfusion according to the thickness and number of kidney arteries; thus, the isolated kidney perfusion system provided by the invention has the advantages of simple structure, widely-available materials, convenient operation, low price, practicality, sufficient perfusion, scientific and reasonable structure and safe and convenient use.

The invention discloses a storage device for kidney transplantation specimens, which relates to the field of medical instruments and comprises a fixedly connected upper box and a lower box. The upper end of the upper box is provided with a movable box door, and the upper box is provided with a The specimen storage mechanism, the lower box is provided with a drive mechanism, the drive mechanism can drive the specimen storage mechanism to rise or fall; it also includes a cold air system, a temperature sensor and a main controller arranged on the upper box, the cold air The system, drive mechanism and temperature sensor are all electrically connected to the main controller; this design is convenient for use and safe for storage.

The invention belongs to the technical field of medical detection, and provides an application of a product for detecting donor-driver cell-free DNA (ddcfDNA) in the preparation of a product for detecting BKVAN, a product for detecting BKVAN and a method for detecting BKAN. The product for detecting ddcfDNA can detect the level of ddcfDNA in urine of an organ transplant recipient, such as a renaltransplant recipient, diagnose whether the organ transplant recipient is a BKVAN or a BKVAN high-risk patient according to the level of the ddcfDNA and realize an early diagnosis of postoperative BKVAN in the organ transplant recipient, and has the advantages of rapidness, accuracy and high sensitivity. The detection method is noninvasive, and greatly reduces the pain of patients.

The invention relates to a tacrolimus slow-release tablet composition capable of being quickly disintegrated, in particular to a medicine composition which is in a tablet form. The composition includes tacrolimus, ethyecellulose, colloid, water-insoluble diluent, water-soluble diluent, disintegrating agent, fluid auxiliary and lubricating agent. The tablet can be quickly disintegrated; meanwhile,after fine particles formed after the tablet is quickly disintegrated enter the gastrointestinal tract, active medicine tacrolimus can be slowly released, and shows the unique features of quick disintegrating and slow release. Besides, the dissolution performance of the tablet under an acid condition basically has no difference from the dissolution performance of the tablet under a weak acid condition. The invention further relates to a preparing method of the tablet composition and clinical treatment application of the tablet composition, as immunosuppression, in preventing graft rejection reactions after a liver or kidney transplantation operation, and treating the graft rejection reactions which cannot be controlled by other immunosuppression drugs after the liver or kidney transplantation operation.

The invention belongs to the technical field of medical animal models, particularly to a rabbit kidney in-vivo low-temperature mechanical perfusion model and a construction method thereof. The rabbit kidney in-vivo low-temperature mechanical perfusion model which serves as a research tool is characterized in that the in-vivo autologous kidney transplant mode is adopted, wherein the kidney transplant low-temperature mechanical perfusion process is copied. The construction method comprises the steps of preoperative preparation; anesthesia, fixation, skin preparation and conventional laparotomy; renal pedicle clipping and abdominal exploration; reperfusion; in-vivo simulation on kidney in-vitro low-temperature MP (Mechanical Perfusion) preservation; vascular suture; bladder colostomy; right kidney excision; abdominal cavity closing; postoperative maintenance. According to the rabbit kidney in-vivo low-temperature mechanical perfusion model, the immunological rejection caused by allogeneic kidney supply is eliminated; meanwhile the kidney is not completely separated and accordingly the vascular suture is easy, the suture time is shortened, the vascular damage is reduced, and the interference of the factors is reduced when the rabbit kidney in-vivo low-temperature mechanical perfusion model is applied to the MP mechanism research; the operation is simple and the repeatability is good.

A method for identifying the risk of developing Chronic Allograft Nephropathy (CAN) in a patient that received a kidney transplant from a donor which comprises identifying the race of the donor; determining the levels of SHROOM 3 expression in a kidney biopsy specimen obtained from the patient at a predetermined time after transplant; comparing the level of SHROOM 3 expression in the biopsy specimen with the levels of SHROOM 3 expression in a control; determining if the level of SHROOM 3 expression in the allograft is significantly higher than in the control, and diagnosing the patient as being at risk for CAN if the level of SHROOM 3 expression in the specimen is significantly higher than in the control.

The present invention relates to a medicine for treating chronic renal failure. The chronic renal failure is the final result of various kidney diseases, but without effective western medicine in clinic yet, and dialysis therapy and renal transplantation price are expensive and not suitable for early and middle patients. The medicine whole formula of the present invention both activates and tonifies, consideration to right and evil, nourishing and releasing integrated, leading nourishing not stagnating evil, releasing not injuring right, can not only delay chronic renal failure course, but also improve or eliminate clinical symptoms, having good curative effect, lower cost characteristic. The present invention concretely is with radix astragali, poria, hedyotis diffusa, serissa foetida, pyrola calliantha, ligusticum chuanxiong, morinda officinalis how, centella asiatica, prepared rhubarb and etc. traditional Chinese medicine to prepare into compound preparation. The present invention also relates to the medicine preparation method. As pharmacological experiment shows the present invention can obviously decrease adenine causing chronic renal failure rat and nephrectomy causing chronic renal failure rat kidney function Crea and BUN value, the present invention can also obviously increase water load rat urinary volume.